LATEST UPDATES » Vol 22, No 09, September 2018 – Doctor Robot - The digital healthcare revolution       » Gene helps rice adapt to colder climates       » 'Longevity protein' found effective in primates       » Korean beef inhibits proliferation of colorectal cancer cells       » First 3D printed human corneas       » Zombie gene protects against cancer in elephants      
China slashes prices of cancer medicine to ensure affordability for all
No tariffs for imported cancer medicine, helping patients save 10 to 20 percent

Even today, cancer is still one of the most difficult diseases to tackle.

According to a research study conducted by the National Cancer Center of China released in 2018, there were about 3.8 million new cases in 2014 in China. That means at least seven new patients are diagnosed with cancer every minute.

In China, the most common forms of cancer in men are lung cancer, gastric cancer and liver cancer. For females, they are breast cancer, lung cancer and colorectal cancer. Deaths from lung cancer are the highest among all cancers.

“Most patients have already reached the late stage of cancer when they are diagnosed. The later they are diagnosed, the fewer methods we could take, and less positive effects we could achieve,” said Dr. Zhang Shucai, director of the Department of Oncology at Beijing Chest Hospital, when explaining why the death rate of lung cancer is relatively higher in China.

Financial burden

But cancer brings more than physical pain to patients, it also brings a tremendous financial burden to them and their families.

Taking medicines for targeted therapy is one of the most effective treatments for cancer patients. But many medicines are imported, and are not covered by the country’s public health insurance. This means that cancer medicine can cost a patient hundreds of thousands of yuan out of pocket every year.

Some families barely scrape by in order to keep their loved ones alive, with some even smuggling cheap generic drugs from India.

However, the situation has improved since last September.

Access for every patient

Through the Chinese government’s procurement and negotiations, the price for imported medicine has dropped drastically. Most cancer medicines were also put on the list of drugs that are covered by public health insurance.

This year, Chinese Premier Li Keqiang announced that there will be no tariffs for imported cancer medicine. That will help patients save a further 10 to 20 percent.

So just how much money can a cancer patient save?

Take the drug Bevacizumab, one of the most commonly prescribed medicines for lung cancer, as an example. Before September 2017, lung cancer patients had to spend 25,985 yuan every month. After the price was reduced last September, the drug came down to 9,990 yuan per month. That means a price cut of more than 50 percent.

After medical insurance, patients only need to pay 1,898 yuan per month, or less than one-tenth of the drug’s cost before price reductions. After tax cuts, the price could go down to 1,518 yuan.

Zhang said even though targeted therapy is effective, few could afford the drug due to high prices. “But now we can feel the change: many more patients can try the medicines for targeted therapy,” he said.

Allowing more imported medicines not only satisfies patients' urgent need for better treatment, it will also spur domestic pharmaceutical companies to develop China's own medicines.

This year, the Chinese government emphasized speeding up the timeline for the tariff cuts, for importing newly developed medicine and adding them under the scope of the country’s public health insurance.

Source: CGTN

Click here for the complete issue.

news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
Asia Pacific Biotech News
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management - Technologies for biotech and pharmaceutical industries
Regenerative technology - Meat of the future
Doctor Robot - The digital healthcare revolution
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy